34
Participants
Start Date
December 1, 2020
Primary Completion Date
August 30, 2023
Study Completion Date
August 30, 2023
Baricitinib
patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
Placebos
patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
CHU Brest, Brest
Ch Morlaix, Morlaix
Chu Bordeaux, Bordeaux
Chu Tours, Tours
CH Le Mans, Le Mans
CHU Montpellier, Montpellier
CHU Nice, Nice
CHU Strasbourg, Strasbourg
Eli Lilly and Company
INDUSTRY
University Hospital, Brest
OTHER